Team of Foreign Heads of Missions in India visit leading Biotech companies in Hyderabad involved in COVID-19 vaccine development
A team of Heads of Foreign Missions and envoys have been briefed about COVID-19 research and Manufacturing at the Bharat Biotech International Limited in Hyderabad and also at the Biological e laboratory. They visited the two laboratories in Hyderabad to have first-hand information about the ongoing efforts to develop vaccines.
Bharat Biotech founder Krishna Ella said the laboratory aims at producing 500 million covaxin doses by the end of next year. He said personalised covaxin is being developed and the first type for children and pregnant mothers. He added the second type for the population with cancer and kidney issues while the third type is for the general population. He further said efforts are also underway to develop nasal vaccines.
He informed that the Bharat Biotech is setting up two more Bio Safety Level -3 laboratories. During his presentations, Mr Krishna Yella said the results of ongoing third phase clinical trials are satisfactory. When asked about when will be covaxin will be rolled out, he said at the earliest and as soon as the necessary approvals were obtained from the government.
Official Correspondent reports, in a significant development, a team of over 60 foreign diplomats who visited the COVID vaccine production facilities in Hyderabad today have expressed satisfaction stating that India is emerging as a global leader in the fight against COVID under the leadership of Prime minister Narendra Modi. They also noted that India has enhanced it’s capabilities in vaccine production and exuded hope that India will meet the requirements of other countries too.
The team comprising high commissioners and government representatives has interacted with the Bharat Biotech team and extensively discussed manufacturing of India’s indigenous COVID-19 vaccine, Covaxin. The Covaxin is being developed by Bharat Biotech in collaboration with the ICMR.
It may be recalled that the Covaxin is currently under phase III trials and the Bharat Biotech Chairman Dr Krishna Ella d the delegates about the progress of the Covaxin. The delegation also visited another company, Biological E, where the Telangana state government also gave a powerpoint presentation. The Biological e authorities informed the delegation that they are producing three types of vaccine simultaneously.